- Home
- BRBR vs ORIC Comparison
BRBR vs ORIC Comparison
Compare BRBR & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRBR | ORIC |
|---|---|---|
| Founded | 2019 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 861.3M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BRBR | ORIC |
|---|---|---|
| Price | $8.63 | $7.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 13 |
| Target Price | ★ $36.63 | $19.73 |
| AVG Volume (30 Days) | ★ 4.2M | 1.6M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | ★ 0.65 | N/A |
| Revenue | ★ $2,316,600,000.00 | N/A |
| Revenue This Year | $6.28 | N/A |
| Revenue Next Year | $5.81 | N/A |
| P/E Ratio | $12.97 | ★ N/A |
| Revenue Growth | ★ 16.05 | N/A |
| 52 Week Low | $7.82 | $7.23 |
| 52 Week High | $63.08 | $14.93 |
Technical Indicators
Market Signals| Indicator | BRBR | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 35.27 | 40.55 |
| Support Level | N/A | N/A |
| Resistance Level | $9.42 | $9.13 |
| Average True Range (ATR) | 0.54 | 0.57 |
| MACD | 0.22 | 0.00 |
| Stochastic Oscillator | 46.25 | 18.92 |
Price Performance
Historical ComparisonAbout BRBR BellRing Brands Inc.
BellRing Brands Inc is a United States-based company engaged in providing nutrition-related products. Its brands, Premier Protein, Dymatize, and PowerBar provides various products including ready-to-drink protein shakes, powders and nutrition bars. The company's products are distributed through a diverse network of channel including club, food, drug and mass, eCommerce, convenience and specialty.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.